Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Gils

Showing results (71-80 of 162) with videos related to

Pageof 17
Sort By:
Therapeutic Drug Monitoring|December 20, 2014
Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab AssaysThomas Van Stappen, Els Brouwers, Sophie Tops, et al.
Clinical Pharmacokinetics|March 30, 2017
Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's DiseaseNiels Vande Casteele, Diane R Mould, Jason Coarse, et al.
Journal of Crohn'S & Colitis|July 13, 2016
Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative ColitisKonstantinos Papamichael, Filip Baert, Sophie Tops, et al.
Plos One|October 3, 2014
Heterobifunctional PEG ligands for bioconjugation reactions on iron oxide nanoparticlesMaarten Bloemen, Thomas Van Stappen, Pieter Willot, et al.
Thrombosis and Haemostasis|July 1, 2016
Haemostatic biomarkers are associated with long-term recurrent vascular events after ischaemic strokeAnnie Pedersen, Petra Redfors, Linnea Lundberg, et al.
Clinical Therapeutics|April 20, 2016
Efficacy and Safety Profile of Anti-tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect ComparisonsMichael Miligkos, Konstantinos Papamichael, Niels Vande Casteele, et al.
Inflammatory Bowel Diseases|September 16, 2014
Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponseKonstantinos Papamichael, Ann Gils, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis|November 27, 2020
Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab ConcentrationsNathalie Van den Berghe, Bram Verstockt, Ann Gils, et al.
The American Journal of Gastroenterology|August 3, 2016
A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel DiseaseThomas Billiet, Erwin Dreesen, Isabelle Cleynen, et al.
Journal of Structural Biology|March 17, 2010
Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differencesMaarten Dewilde, Britt Van De Craen, Griet Compernolle, et al.
Pageof 17

Showing results (71-80 of 162) with videos related to

Sort By:
Pageof 17
Therapeutic Drug Monitoring|December 20, 2014
Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab AssaysThomas Van Stappen, Els Brouwers, Sophie Tops, et al.
Clinical Pharmacokinetics|March 30, 2017
Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's DiseaseNiels Vande Casteele, Diane R Mould, Jason Coarse, et al.
Journal of Crohn'S & Colitis|July 13, 2016
Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative ColitisKonstantinos Papamichael, Filip Baert, Sophie Tops, et al.
Plos One|October 3, 2014
Heterobifunctional PEG ligands for bioconjugation reactions on iron oxide nanoparticlesMaarten Bloemen, Thomas Van Stappen, Pieter Willot, et al.
Thrombosis and Haemostasis|July 1, 2016
Haemostatic biomarkers are associated with long-term recurrent vascular events after ischaemic strokeAnnie Pedersen, Petra Redfors, Linnea Lundberg, et al.
Clinical Therapeutics|April 20, 2016
Efficacy and Safety Profile of Anti-tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect ComparisonsMichael Miligkos, Konstantinos Papamichael, Niels Vande Casteele, et al.
Inflammatory Bowel Diseases|September 16, 2014
Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponseKonstantinos Papamichael, Ann Gils, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis|November 27, 2020
Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab ConcentrationsNathalie Van den Berghe, Bram Verstockt, Ann Gils, et al.
The American Journal of Gastroenterology|August 3, 2016
A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel DiseaseThomas Billiet, Erwin Dreesen, Isabelle Cleynen, et al.
Journal of Structural Biology|March 17, 2010
Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differencesMaarten Dewilde, Britt Van De Craen, Griet Compernolle, et al.
Pageof 17